/

Sociétés

Io

Non vérifié

Io Therapeutics, Inc.

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologieMédecine Santé Bien-être

7 communiqués de presse

Voir tous les communiqués de presse

23/12/2024

Biotechnologie

Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis

Source

Io Therapeutics, Inc.

Émetteur

1,00

0

11/12/2024

Biotechnologie

Médecine Santé Bien-être

Annonces Économiques

Io Therapeutics, Inc., announces presentation of data from studies of its RAR gamma agonist compound IRX5010 in treatment of a mouse model of triple negative breast cancer, demonstrating combination treatment effects with an anti-PDL-1 monoclonal antibody checkpoint inhibitor

Source

Io Therapeutics, Inc.

Émetteur

1,00

0

08/11/2024

Biotechnologie

Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers

Source

Io Therapeutics, Inc.

Émetteur

1,00

0

18/09/2024

Biotechnologie

Médecine Santé Bien-être

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging

Source

Io Therapeutics, Inc.

Émetteur

1,00

0

16/07/2024

Biotechnologie

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis (ALS)

Source

Io Therapeutics, Inc.

Émetteur

1,00

0

09/07/2024

Biotechnologie

Médecine Santé Bien-être

Annonces Économiques

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease

Source

Io Therapeutics, Inc.

Émetteur

1,00

0

08/07/2024

Biotechnologie

Médecine Santé Bien-être

Annonces Économiques

Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound

Source

Io Therapeutics, Inc.

Émetteur

1,00

0

Followers

0

Compatibilité

0